The association between repeated doses of vaginal PGE2 (Dinoprostone, Prostin®) and both maternal and neonatal outcomes among women in the north of Jordan
Objective: To evaluate the association between repeated doses of vaginal PGE2 and the maternal and neonatal outcomes for primigravid and multiparous women. Study design: A retrospective descriptive study was conducted at a teaching university hospital in Jordan. The study involved 885 women with sin...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
IMR Press
2020-06-01
|
| Series: | Clinical and Experimental Obstetrics & Gynecology |
| Subjects: | |
| Online Access: | https://www.imrpress.com/journal/CEOG/47/3/10.31083/j.ceog.2020.03.5322 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849324859706834944 |
|---|---|
| author | A.M. Sindiani H.M. Rawashdeh E.H. Alshdaifat O.F. Altal H. Yaseen A.A. Alhowary |
| author_facet | A.M. Sindiani H.M. Rawashdeh E.H. Alshdaifat O.F. Altal H. Yaseen A.A. Alhowary |
| author_sort | A.M. Sindiani |
| collection | DOAJ |
| description | Objective: To evaluate the association between repeated doses of vaginal PGE2 and the maternal and neonatal outcomes for primigravid and multiparous women. Study design: A retrospective descriptive study was conducted at a teaching university hospital in Jordan. The study involved 885 women with singleton live fetuses; these women had been admitted to the labor ward for an induction of labor by vaginal PGE2 (Dinoprostone, Prostin®) for different indications from January 2015 to December 2016. The women were classified according to parity into two main groups, namely, primigravid and multiparous. In the primigravid group, the women who had received two or fewer doses of a vaginal PGE2 tablet (3 mg Dinoprostone) were compared with those who had received a PGE2 tablet three times. In the multiparous group, the women who had received one or two doses of half the usual vaginal PGE2 tablet (1.5 mg Dinoprostone) were compared with those who had received the same dose three times. The main outcomes studied were the cesarean section rate and the APGAR score. Results: There was a statistically significant association, namely, X2 (1) = 13.96, P = 0.001, between the repeated doses of PGE2 and the mode of delivery. This indicates that primigravid women who received more than two doses of PGE2 were more likely to have a cesarean section (65.5%, n = 57 out of 87) compared with primigravid women who received two or fewer doses of PGE2 (42.9%, n = 132 out of 308). There was no significant association between repeated doses of PGE2 insertion and admission either to the nursery or the neonatal intensive care unit (NICU) X2 (1) = 2.11, P = 0.14. Moreover, the results also showed that there was no significant association between repeated doses of PGE2 insertion and the APGAR score X2 (1) = 0.06, P = 0.88. For multiparous women, there was no statistically significant association X2 (1) = 2.15, P = 0.14 between repeated doses of PGE2 insertion and the mode of delivery. Conclusion: In both groups of primigravid and multiparous women, the third dose of vaginal PGE2 was not associated with a significant increase in maternal or neonatal morbidity. In the primigravid group, despite the third dose of PGE2 being associated with a higher rate of cesarean section in comparison with two or fewer doses of it, nearly a third of the women nevertheless achieved vaginal delivery. In the multiparous group, the third dose of PGE2 was not associated with a higher rate of cesarean sections. |
| format | Article |
| id | doaj-art-82fb7af9fa6a41aa99380d1512fb2cc4 |
| institution | Kabale University |
| issn | 0390-6663 |
| language | English |
| publishDate | 2020-06-01 |
| publisher | IMR Press |
| record_format | Article |
| series | Clinical and Experimental Obstetrics & Gynecology |
| spelling | doaj-art-82fb7af9fa6a41aa99380d1512fb2cc42025-08-20T03:48:35ZengIMR PressClinical and Experimental Obstetrics & Gynecology0390-66632020-06-0147332933410.31083/j.ceog.2020.03.5322S0390-6663(20)00261-4The association between repeated doses of vaginal PGE2 (Dinoprostone, Prostin®) and both maternal and neonatal outcomes among women in the north of JordanA.M. Sindiani0H.M. Rawashdeh1E.H. Alshdaifat2O.F. Altal3H. Yaseen4A.A. Alhowary5Department of Obstetrics and Gynecology, Faculty of Medicine, Jordan University of Science and Technology, Irbid, JordanDepartment of Obstetrics and Gynecology, Faculty of Medicine, Jordan University of Science and Technology, Irbid, JordanDepartment of Obstetrics and Gynecology, Faculty of Medicine, Jordan University of Science and Technology, Irbid, JordanDepartment of Obstetrics and Gynecology, Faculty of Medicine, Jordan University of Science and Technology, Irbid, JordanDepartment of Obstetrics and Gynecology, Faculty of Medicine, Jordan University of Science and Technology, Irbid, JordanDepartment of Anaesthesia, Jordan University of Science and Technology, Irbid, JordanObjective: To evaluate the association between repeated doses of vaginal PGE2 and the maternal and neonatal outcomes for primigravid and multiparous women. Study design: A retrospective descriptive study was conducted at a teaching university hospital in Jordan. The study involved 885 women with singleton live fetuses; these women had been admitted to the labor ward for an induction of labor by vaginal PGE2 (Dinoprostone, Prostin®) for different indications from January 2015 to December 2016. The women were classified according to parity into two main groups, namely, primigravid and multiparous. In the primigravid group, the women who had received two or fewer doses of a vaginal PGE2 tablet (3 mg Dinoprostone) were compared with those who had received a PGE2 tablet three times. In the multiparous group, the women who had received one or two doses of half the usual vaginal PGE2 tablet (1.5 mg Dinoprostone) were compared with those who had received the same dose three times. The main outcomes studied were the cesarean section rate and the APGAR score. Results: There was a statistically significant association, namely, X2 (1) = 13.96, P = 0.001, between the repeated doses of PGE2 and the mode of delivery. This indicates that primigravid women who received more than two doses of PGE2 were more likely to have a cesarean section (65.5%, n = 57 out of 87) compared with primigravid women who received two or fewer doses of PGE2 (42.9%, n = 132 out of 308). There was no significant association between repeated doses of PGE2 insertion and admission either to the nursery or the neonatal intensive care unit (NICU) X2 (1) = 2.11, P = 0.14. Moreover, the results also showed that there was no significant association between repeated doses of PGE2 insertion and the APGAR score X2 (1) = 0.06, P = 0.88. For multiparous women, there was no statistically significant association X2 (1) = 2.15, P = 0.14 between repeated doses of PGE2 insertion and the mode of delivery. Conclusion: In both groups of primigravid and multiparous women, the third dose of vaginal PGE2 was not associated with a significant increase in maternal or neonatal morbidity. In the primigravid group, despite the third dose of PGE2 being associated with a higher rate of cesarean section in comparison with two or fewer doses of it, nearly a third of the women nevertheless achieved vaginal delivery. In the multiparous group, the third dose of PGE2 was not associated with a higher rate of cesarean sections.https://www.imrpress.com/journal/CEOG/47/3/10.31083/j.ceog.2020.03.5322inductionlaborpge2cesarean section |
| spellingShingle | A.M. Sindiani H.M. Rawashdeh E.H. Alshdaifat O.F. Altal H. Yaseen A.A. Alhowary The association between repeated doses of vaginal PGE2 (Dinoprostone, Prostin®) and both maternal and neonatal outcomes among women in the north of Jordan Clinical and Experimental Obstetrics & Gynecology induction labor pge2 cesarean section |
| title | The association between repeated doses of vaginal PGE2 (Dinoprostone, Prostin®) and both maternal and neonatal outcomes among women in the north of Jordan |
| title_full | The association between repeated doses of vaginal PGE2 (Dinoprostone, Prostin®) and both maternal and neonatal outcomes among women in the north of Jordan |
| title_fullStr | The association between repeated doses of vaginal PGE2 (Dinoprostone, Prostin®) and both maternal and neonatal outcomes among women in the north of Jordan |
| title_full_unstemmed | The association between repeated doses of vaginal PGE2 (Dinoprostone, Prostin®) and both maternal and neonatal outcomes among women in the north of Jordan |
| title_short | The association between repeated doses of vaginal PGE2 (Dinoprostone, Prostin®) and both maternal and neonatal outcomes among women in the north of Jordan |
| title_sort | association between repeated doses of vaginal pge2 dinoprostone prostin r and both maternal and neonatal outcomes among women in the north of jordan |
| topic | induction labor pge2 cesarean section |
| url | https://www.imrpress.com/journal/CEOG/47/3/10.31083/j.ceog.2020.03.5322 |
| work_keys_str_mv | AT amsindiani theassociationbetweenrepeateddosesofvaginalpge2dinoprostoneprostinandbothmaternalandneonataloutcomesamongwomeninthenorthofjordan AT hmrawashdeh theassociationbetweenrepeateddosesofvaginalpge2dinoprostoneprostinandbothmaternalandneonataloutcomesamongwomeninthenorthofjordan AT ehalshdaifat theassociationbetweenrepeateddosesofvaginalpge2dinoprostoneprostinandbothmaternalandneonataloutcomesamongwomeninthenorthofjordan AT ofaltal theassociationbetweenrepeateddosesofvaginalpge2dinoprostoneprostinandbothmaternalandneonataloutcomesamongwomeninthenorthofjordan AT hyaseen theassociationbetweenrepeateddosesofvaginalpge2dinoprostoneprostinandbothmaternalandneonataloutcomesamongwomeninthenorthofjordan AT aaalhowary theassociationbetweenrepeateddosesofvaginalpge2dinoprostoneprostinandbothmaternalandneonataloutcomesamongwomeninthenorthofjordan AT amsindiani associationbetweenrepeateddosesofvaginalpge2dinoprostoneprostinandbothmaternalandneonataloutcomesamongwomeninthenorthofjordan AT hmrawashdeh associationbetweenrepeateddosesofvaginalpge2dinoprostoneprostinandbothmaternalandneonataloutcomesamongwomeninthenorthofjordan AT ehalshdaifat associationbetweenrepeateddosesofvaginalpge2dinoprostoneprostinandbothmaternalandneonataloutcomesamongwomeninthenorthofjordan AT ofaltal associationbetweenrepeateddosesofvaginalpge2dinoprostoneprostinandbothmaternalandneonataloutcomesamongwomeninthenorthofjordan AT hyaseen associationbetweenrepeateddosesofvaginalpge2dinoprostoneprostinandbothmaternalandneonataloutcomesamongwomeninthenorthofjordan AT aaalhowary associationbetweenrepeateddosesofvaginalpge2dinoprostoneprostinandbothmaternalandneonataloutcomesamongwomeninthenorthofjordan |